Pemetrexed is classified as a folate analogue metabolic inhibitor, primarily utilized in the treatment of non-small cell lung cancer and malignant pleural mesothelioma. It can be administered alone or in combination with other chemotherapeutic agents. The drug is crucial in managing these cancers, particularly in patients who have not responded to platinum-based chemotherapy. Pemetrexed functions by inhibiting the enzymes involved in the synthesis of nucleotides, thereby blocking the proliferation of cancer cells. Common side effects may include fatigue, nausea, and loss of appetite, but these typically resolve over time. In simple terms, Pemetrexed helps fight specific types of lung cancer and mesothelioma by slowing down the growth of cancer cells.
Pemetrexed inhibits multiple enzymes involved in folate metabolism, specifically thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase, leading to decreased nucleotide production and subsequent inhibition of DNA synthesis in cancer cells.
No published brands for this salt yet.